StreetInsider.com News Articles

Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event

Tue, 08 Sep 2026 07:05:00 -0400

WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that it will host an Obexelimab IgG4-RD Investor Event virtually on Tuesday, September 29, 2026, from 8:00 – 9:30 a.m. ET.

Zenas’ management team will be joined by Guy Katz, M.D., Division of Rheumatology, Inflammation, and Immunity, Massachusetts General Hospital, Boston, MA, USA. The event will provide an overview of

Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event

Tue, 08 Sep 2026 07:05:00 -0400

Zenas’ management team will be joined by Guy Katz, M.D., Division of Rheumatology, Inflammation, and Immunity, Massachusetts General Hospital, Boston, MA, USA. The event will provide an overview of

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

Fri, 04 Sep 2026 07:05:00 -0400

WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced management’s presentations at the following investor conferences:

Citi Biopharma Back to School Conference on Wednesday, September 9, 2026, at 4:20 p.m. ET
Morgan Stanley 24^th Annual Global Healthcare Conference on Monday, September 14, 2026, at 4:05 p.m. ET
H.C. Wainwright 28^th Annual Global Investment Conference on Wednesday, September 16,

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

Fri, 04 Sep 2026 07:05:00 -0400

Citi Biopharma Back to School Conference on Wednesday, September 9, 2026, at 4:20 p.m. ET
Morgan Stanley 24^th Annual Global Healthcare Conference on Monday, September 14, 2026, at 4:05 p.m. ET
H.C. Wainwright 28^th Annual Global Investment Conference on Wednesday, September 16,

Form SCHEDULE 13D/A Zenas BioPharma, Inc. Filed by: Enavate Sciences GP, LLC

Wed, 19 Aug 2026 18:50:00 -0400

si-local-file:///var/storage/secattach/20260819/26951465.html

Form SCHEDULE 13D/A Zenas BioPharma, Inc. Filed by: Enavate Sciences GP, LLC

Wed, 19 Aug 2026 18:50:00 -0400

si-local-file:///var/storage/secattach/20260819/26951465.html

Form 144 Zenas BioPharma, Inc. Filed by: Zebra Aggregator, LP

Wed, 19 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260819/26950256.html

Form 144 Zenas BioPharma, Inc. Filed by: Zebra Aggregator, LP

Wed, 19 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260819/26950256.html

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 18 Aug 2026 16:15:00 -0400

WALTHAM, Mass., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that on August 17, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted an aggregate of 11,000 restricted stock units of the Company’s common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees’ entry into employment with the Company, in

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 18 Aug 2026 16:15:00 -0400

Form SCHEDULE 13D/A Zenas BioPharma, Inc. Filed by: SR ONE CAPITAL MANAGEMENT, LLC

Mon, 17 Aug 2026 19:00:00 -0400

si-local-file:///var/storage/secattach/20260817/26939234.html

Form SCHEDULE 13D/A Zenas BioPharma, Inc. Filed by: SR ONE CAPITAL MANAGEMENT, LLC

Mon, 17 Aug 2026 19:00:00 -0400

si-local-file:///var/storage/secattach/20260817/26939234.html

Zenas Biopharma (ZBIO) PT Raised to $32 at Morgan Stanley

Mon, 17 Aug 2026 08:58:59 -0400

Morgan Stanley analyst Judah C. Frommer raised the price target on Zenas Biopharma (NASDAQ: ZBIO) to $32.00 (from $22.00) while maintaining a Equalweight rating.

Zenas Biopharma (ZBIO) PT Raised to $32 at Morgan Stanley

Fri, 14 Aug 2026 08:35:45 -0400

Morgan Stanley analyst Judah C. Frommer raised the price target on Zenas Biopharma (NASDAQ: ZBIO) to $32.00 (from $22.00) while maintaining a Equalweight rating.

Zenas BioPharma, Inc. (ZBIO) Reports Q2 Loss of $1.77

Thu, 13 Aug 2026 07:22:12 -0400

Zenas BioPharma, Inc. (NASDAQ: ZBIO) reported Q2 EPS of ($1.77).Revenue for the quarter came in at $1 million.

For earnings history and earnings-related data on Zenas BioPharma, Inc. (ZBIO) click here.

Form 10-Q Zenas BioPharma, Inc. For: Jun 30

Thu, 13 Aug 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260813/26916386.html

Form 10-Q Zenas BioPharma, Inc. For: Jun 30

Thu, 13 Aug 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260813/26916386.html

Form 8-K Zenas BioPharma, Inc. For: Aug 12

Thu, 13 Aug 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260813/26916306.html

Form 8-K Zenas BioPharma, Inc. For: Aug 12

Thu, 13 Aug 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260813/26916306.html

Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 13 Aug 2026 07:00:00 -0400

- Obexelimab BLA submission for the treatment of IgG4-RD accepted by FDA; PDUFA target action date of May 27, 2027 -

- New study data confirm bioequivalence of obexelimab single-dose prefilled autoinjector pen compared to prefilled syringes -

- Obexelimab global Phase 2 SunStone SLE trial topline results expected in Q4 2026 -

- ZB021 (oral IL-17AA/AF inhibitor) dosing ongoing in Phase 1 trial; initial clinical data expected by year-end -

- Four Orelabrutinib abstracts accepted for poster presentation at MSToronto 2026 -

Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 13 Aug 2026 07:00:00 -0400

- Obexelimab BLA submission for the treatment of IgG4-RD accepted by FDA; PDUFA target action date of May 27, 2027 -

- New study data confirm bioequivalence of obexelimab single-dose prefilled autoinjector pen compared to prefilled syringes -

- Obexelimab global Phase 2 SunStone SLE trial topline results expected in Q4 2026 -

- ZB021 (oral IL-17AA/AF inhibitor) dosing ongoing in Phase 1 trial; initial clinical data expected by year-end -

- Four Orelabrutinib abstracts accepted for poster presentation at MSToronto 2026 -

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 17 Jul 2026 16:15:00 -0400

WALTHAM, Mass., July 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on July 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 35,750 shares of the Company’s common stock (“Stock Options”) and an aggregate of 79,050 restricted stock units of the Company’s common stock (“RSUs”) to newly hired employees of

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 17 Jul 2026 16:15:00 -0400

Form 4 Zenas BioPharma, Inc. For: Jun 15 Filed by: Nunn Jason Raleigh

Wed, 17 Jun 2026 18:10:00 -0400

si-local-file:///var/storage/secattach/20260617/26661212.html

Form 4 Zenas BioPharma, Inc. For: Jun 15 Filed by: Nunn Jason Raleigh

Wed, 17 Jun 2026 18:10:00 -0400

si-local-file:///var/storage/secattach/20260617/26661212.html